Astec Lifesciences Limited (ASTEC) AI Stock Analysis

• Market Cap: ₹12.50B
• Dividend Yield: N/A
• Average Volume (3M): 412.49K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.27
• Revenue Growth: 1.54%
• EPS Growth: -8.04%
• Country: IN
• Employees: 606
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Agricultural Inputs
• EPS (TTM): -7.04
• Shares Outstanding: 22,282,238
• 10 Day Avg. Volume: 47,730
• 30 Day Avg. Volume: 412,490
• PEG Ratio: -0.06
• Price to Book (P/B): 6.06
• Price to Sales (P/S): 3.73
• P/FCF Ratio: -47.04
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -21.45
• Revenue Forecast (FY): ₹4.60B

• Rating: 52 Neutral
• Price Target: ₹567.00 ▼(-19.40% Downside)
• Action: Reiterated Date: 12/02/25
• Date: Action: Reiterated 12/02/25

The overall stock score is primarily impacted by the company's poor financial performance, characterized by declining revenue, negative margins, and liquidity issues. While technical analysis shows positive momentum, the negative P/E ratio and lack of dividend yield weigh heavily on the valuation, resulting in a moderate overall score.

Positive Factors

Integrated agrochemical manufacturing

A vertically integrated model spanning active ingredients, intermediates and formulations provides durable operational control over product mix and customer relationships. This breadth supports margin management, captive manufacturing utilization and multiple B2B/B2C revenue channels over the medium term.

Exposure to essential Agricultural Inputs sector

Operating in the agricultural inputs sector gives structural demand support since crop-protection chemicals are staple inputs for farming. This end-market resilience tends to sustain base demand and reduces revenue cyclicality risk relative to discretionary sectors over a 2–6 month horizon.

Reported EPS growth

A materially positive EPS growth metric suggests recent per-share earnings improvement despite top-line pressures. This implies potential operational leverage, cost controls, or mix shifts that could support margin recovery and improve profitability sustainability if maintained by management actions.

Negative Factors

Declining revenue and negative margins

Sustained revenue decline coupled with negative gross and net margins indicates core profitability erosion. This undermines the company's ability to generate internal funding for growth, weakens competitive position versus peers, and requires structural fixes to restore long-term viability.

Weak cash generation / negative free cash flow

Consistent negative operating cash flow and free cash flow signal liquidity stress and weak conversion of earnings to cash. This constrains capex, working capital and debt servicing, raising the likelihood of external financing needs and limiting strategic flexibility over the medium term.

High and rising leverage

Increasing leverage and a falling equity ratio elevate financial risk through higher interest burden and refinancing vulnerability. Elevated liabilities reduce balance sheet resilience, limit ability to invest in growth projects, and heighten downside in a downturn absent rapid deleveraging.

Astec Lifesciences Limited Business Overview & Revenue Model

Company Description

Astec LifeSciences Limited, together with its subsidiaries, manufactures, distributes, and sells agrochemicals active ingredients and pharmaceutical intermediates in India. It manufactures a range of fungicides, insecticides, herbicides, and intermediates, such as triazole fungicides, heterocyclic herbicides, sulfonyl urea herbicides, synthetic pyrethroids, alkyl and aryl magnesium halides, mixed metal halides, and silane derivatives; fluorinated aromatic amines, pyridine derivatives, aromatic carboxylic acids, benzyl alcohols, ketones and benzophenones, and heterocyclic mercaptans; fluorinated aromatic, aliphatic, and heterocyclic intermediates; heterocyclic mercaptans, thiopyrimidines, aromatic mercaptans, heterocyclic sulfonyl chlorides, heterocyclic sulphonamides, heterocyclic carbamates, thiourium salts, alkyl and aryl chloroformates, substituted pyrimidine diones, and pyrazolones; and substituted 1,2- and 1,3- pyrimidines. The company's products also comprise pyrazolyl aromatic ketones, morpholine derivatives, aromatic azo compounds, substituted triazines, imidate ethers, mesylated intermediates, substituted epoxides, ketals and bromo ketals, aromatic and aliphatic ethers, cyclopropyl ethers, cyclopropyl aldehydes and ketones, conjugated ketones, acetophenone derivatives, pinacolone derivatives, aliphatic and aromatic carboxylic acids, aliphatic and aromatic acid chlorides, halogenated and non-halogenated anhydrides, aliphatic alkenes, and halo alkanes; and aliphatic and aromatic brominated derivatives, cyanides, esters, carboxamides, amines, and alcohols and diols. It also exports its products. The company was incorporated in 1994 and is based in Mumbai, India. Astec LifeSciences Limited is a subsidiary of Godrej Agrovet Limited.

How the Company Makes Money

Astec Lifesciences primarily makes money by selling agrochemical products across different points of the crop-protection value chain: (1) sale of active ingredients (technical) and key intermediates manufactured at its facilities to agrochemical companies (B2B supply), and (2) sale of formulated crop-protection products. Revenue is generated from product sales under customer purchase contracts/orders, with earnings driven by volumes sold, product mix (higher-value active ingredients vs. intermediates), pricing (influenced by agrochemical demand and input costs), and manufacturing utilization/efficiency. If the company earns material income via contract manufacturing, licensing, or long-term strategic supply partnerships, null (specific details not available in the provided context).

Astec Lifesciences Limited Financial Statement Overview

Summary

Astec Lifesciences Limited faces significant financial challenges. The income statement highlights declining revenue and profitability, with negative margins impacting overall performance. The balance sheet shows high leverage and decreasing equity ratios, increasing financial risk. Cash flow difficulties, marked by negative free cash flow, further exacerbate the situation, suggesting liquidity constraints and a need for strategic financial management.

Income Statement

The income statement shows a decline in revenue from 2023 to 2025, with a significant drop in gross profit and net income, resulting in negative margins. The company has experienced negative net profit margins in the most recent years, indicating profitability issues. The revenue growth has been negative, reflecting a challenging market environment or operational difficulties.

Balance Sheet

The balance sheet indicates high leverage with an increasing debt-to-equity ratio over the years, reflecting financial risk. The equity ratio has also decreased, signaling reduced asset backing by equity. Although the company maintains a positive stockholder's equity, the increasing liabilities pose a risk to financial stability.

Cash Flow

The cash flow statement reveals negative free cash flow and operating cash flow in recent years, highlighting liquidity issues. The operating cash flow to net income ratio is unfavorable, indicating a struggle to convert income into cash. Consistently negative free cash flow growth raises concerns about the company’s ability to sustain operations without external financing.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	3.78B	3.81B	4.58B	6.28B	6.77B	5.55B
Gross Profit	1.12B	-685.16M	1.33B	2.27B	2.86B	2.10B
EBITDA	-150.01M	-662.07M	-2.69M	893.14M	1.65B	1.19B
Net Income	-1.14B	-1.35B	-469.30M	255.65M	898.59M	650.49M
Balance Sheet
Total Assets	8.83B	8.81B	9.75B	9.79B	8.97B	6.78B
Cash, Cash Equivalents and Short-Term Investments	96.91M	8.55M	16.47M	27.54M	33.44M	15.42M
Total Debt	3.67B	5.55B	4.94B	3.41B	2.79B	1.87B
Total Liabilities	4.69B	6.46B	6.05B	5.60B	5.00B	3.68B
Stockholders Equity	4.14B	2.35B	3.69B	4.19B	3.96B	3.09B
Cash Flow
Free Cash Flow	-234.96M	-302.20M	-1.25B	-426.03M	-803.74M	-1.11B
Operating Cash Flow	-199.52M	-83.99M	102.21M	746.56M	236.04M	-81.62M
Investing Cash Flow	-73.41M	-152.30M	-1.35B	-1.13B	-1.04B	-731.10M
Financing Cash Flow	297.62M	237.33M	1.25B	377.70M	804.77M	813.36M

Astec Lifesciences Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 703.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ASTEC, the sentiment is Negative. The current price of 703.5 is above the 20-day moving average (MA) of 614.59, above the 50-day MA of 620.43, and below the 200-day MA of 752.07, indicating a bearish trend. The MACD of -14.77 indicates Positive momentum. The RSI at 32.14 is Neutral, neither overbought nor oversold. The STOCH value of 15.66 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ASTEC.

Astec Lifesciences Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IGPL	66 Neutral	₹11.82B	-28.19	―	2.59%	-10.71%	-40.89%
PUNJABCHEM	64 Neutral	₹12.63B	26.88	―	0.24%	10.70%	32.65%
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
IOLCP	60 Neutral	₹21.80B	29.38	―	0.97%	5.74%	16.06%
ASTEC	52 Neutral	₹12.50B	-25.02	―	―	1.54%	-8.04%
HERANBA	49 Neutral	₹7.17B	-10.64	―	0.39%	―	―
UNIENTER	46 Neutral	₹6.68B	-247.22	―	0.34%	―	―

Astec Lifesciences Limited Corporate Events

Astec Lifesciences fully exits small solar SPV stake in Clean Max Andes

Astec Lifesciences Limited has exited its investment in Clean Max Andes Private Limited, a special purpose vehicle created with Clean Max Enviro Energy Solutions for group captive solar power generation, by selling its entire 26% equity stake. The 2,600 shares with a face value of Rs.10 each were sold for a total consideration of Rs.26,000 to Clean Max Enviro Energy Solutions on March 9, 2026, with completion expected by March 10, 2026, indicating a small, non-related party divestment that is not material to turnover or net worth.

The buyer does not belong to Astec’s promoter or group companies, and the transaction is confirmed as not being a related party deal under securities regulations. As the disinvestment pertains to a minor SPV and falls outside any scheme of arrangement or slump sale, the move appears to be a routine portfolio rationalisation with limited direct financial impact, while still signaling a tidy exit from a non-core solar power vehicle.

Astec LifeSciences Files SEBI Demat Compliance Certificate for December Quarter

Astec LifeSciences Limited has informed the Indian stock exchanges that it has received a compliance certificate from its registrar and share transfer agent, Bigshare Services Pvt. Ltd., for the quarter ended 31 December 2025, confirming adherence to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The registrar has certified that no securities were received for dematerialisation during the quarter, and therefore no share certificates were mutilated, cancelled or had their ownership substituted in favour of depositories, underscoring a period of no demat-related activity and reinforcing the company’s ongoing regulatory compliance in its securities handling processes.